User:Mr. Ibrahem/Tixagevimab/cilgavimab

Tixagevimab/cilgavimab, sold under the brand name Evusheld, is a medication used to prevent COVID-19 before exposure. It may be used in those who weight more than 40 kg or are older than 12 years. It is given by injection into a muscle. Evidence supports benefits for up to six month.

Common side effects are allergic reactions, headaches, tiredness, and pain at the site of injection. Other serious side effects may include anaphylaxis and heart problems. Safety in pregnancy is unclear. It is a combination of two monoclonal antibody, tixagevimab and cilgavimab. It works by binding the spike protein of SARS-CoV-2 which prevents it from entering cells.

The combination was approved for medical use in Europe in March and in Canada in April of 2022. In the United States it received Emergency Use Authorization in December of 2021. In the United States the government pays about 855 USD per dose. The cost to the individual is generally less than 10 USD.